Weight loss
An FDA-approved treatment for rare genetic forms of obesity caused by a broken appetite-signaling pathway in the brain.
Start here
Setmelanotide is an FDA-approved medication for rare genetic forms of obesity caused by defects in the brain's appetite-control (melanocortin (a hormone system controlling pigment and appetite)) pathway. It reduces the insatiable hunger these conditions cause 14 and produced 10-23% weight loss in its pivotal clinical trials. It is approved for specific genetic conditions, including POMC, PCSK1, or LEPR deficiency and Bardet-Biedl syndrome 6, not for general weight loss, and is given as a once-daily injection under the skin 6.
Setmelanotide is a brain hormone activator that works like a master switch for appetite control. In people with rare genetic defects, this appetite switch gets stuck in the 'on' position, causing extreme hunger and obesity from childhood. Setmelanotide turns that switch back off by activating the melanocortin-4 receptor in the brain, telling your body to eat less and feel satisfied with smaller meals.
Setmelanotide (RM-493) is a strong, selective agonist (a drug that switches on a receptor) of the melanocortin-4 receptor (MC4R), a receptor found mostly in the paraventricular and dorsomedial hypothalamus (two hunger-control areas of the brain). Switching on MC4R is critical for cutting appetite and raising energy use in the leptin-melanocortin signaling pathway (the brain's hunger-control chain). Setmelanotide switches on MC4R directly, downstream of POMC neurons (brain cells that help signal fullness). So it bypasses upstream defects: in leptin signaling (LEPR), in making POMC (POMC, PCSK1), or in the signal-passing steps for leptin. This restores normal appetite suppression in people with monogenic obesity (obesity caused by a change in a single gene). Its EC50 for human MC4R is approximately 0.2 nM (EC50 is the amount needed for half of the maximum effect, so a low number means high potency), which makes it highly selective and potent. By switching on MC4R on POMC neurons and other appetite-controlling circuits, setmelanotide reduces hyperphagia (extreme hunger), increases fullness, and promotes weight loss specifically in patients with POMC, PCSK1, or LEPR deficiency. These conditions cause severe obesity that is hard to treat because of a fault in the leptin-melanocortin pathway.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Weight Management
Dramatic weight reduction (10-23%) in patients with rare genetic obesity by restoring MC4R-mediated satiety signaling that is absent due to upstream pathway mutations
Metabolic Health
Comprehensive metabolic improvement including BMI reduction, improved lipid profiles, and resolution of hyperphagia-driven metabolic dysfunction
Quality of Life
Transformative reduction in insatiable hunger (hyperphagia) that characterizes monogenic obesity, dramatically improving daily functioning and psychosocial wellbeing
The most-asked question
Setmelanotide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 3 mg, once daily.
First 2 weeks
2 mg
FDA-approved starting dose of Imcivree for obesity from BBS or from POMC/PCSK1/LEPR deficiency (rare genetic conditions) in patients 2 years and older; injected on waking 6. (Obesity from damage to the hypothalamus, the brain's appetite center, starts lower at 0.5 mg daily.)
Ongoing
3 mg
Recommended maintenance and maximum dose after you have tolerated 2 mg for 2 weeks; used in the first approval and the main trials 16. Effective for obesity caused by the MC4R pathway (the brain's fullness-signal pathway) and for obesity from damage to the hypothalamus (the brain's appetite center) 23.
The ceiling: 3 mg (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Setmelanotide:
Add the recommended volume of bacteriostatic water to the Setmelanotide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Setmelanotide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Setmelanotide's recorded schedule.
Injection sites & technique
Injection under the skin (into the fatty tissue just under the skin)—allows steady absorption and can be self-administered at home after proper training
Timing
Administer Setmelanotide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Setmelanotide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Setmelanotide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
The most characteristic side effect, occurring in >60% of patients. Results from off-target activation of MC1R on melanocytes. 6 Manifests as generalized darkening of skin that develops gradually over weeks to months.
What to do An expected effect of the drug switching on melanocortin (a hormone system controlling pigment and appetite) receptors (the targets that also control skin color). Check your skin at regular intervals. Get a baseline skin exam and repeat exams, including dermoscopy (a magnified look at moles), to keep an eye on moles. The darkening may partly fade if you stop treatment.
Local reactions at the injection site: redness, itching, hard lumps, and mild pain. Reported in about 20-30% of patients in clinical trials.
What to do Rotate injection sites between abdomen, thigh, and upper arm. Clean site before injection. Apply cold compress if needed. Reactions typically mild and self-limiting.
Reported in clinical trials, 6 typically mild to moderate. May be related to central MC4R-mediated effects on appetite and gastrointestinal motility.
What to do Usually resolves with continued treatment. Take with food if helpful. Slow dose titration (stepping the dose up gradually) may reduce incidence.
Gastrointestinal disturbance reported in some patients, generally mild and transient 6.
What to do Maintain adequate hydration. Typically self-limiting and does not require dose adjustment.
Worth knowing about, but most people never see these.
Darkening of hair and changes in melanocytic nevi (new or enlarged moles) related to MC1R activation on melanocytes. Less common than general skin hyperpigmentation.
What to do Regular dermatological surveillance recommended. New or changing moles should be evaluated by dermatology. Document baseline nevi before treatment initiation.
Rare, but if any of these happen, stop and contact a medical professional.
Cases of depression and suicidal ideation have been reported during clinical trials. Patients should be monitored for neuropsychiatric symptoms, particularly during the first months of treatment 6.
What to do Screen patients for depression and suicidal ideation before starting treatment. Monitor mood and mental health at each visit. Discontinue if clinically significant depression or suicidal ideation develops. Refer to mental health professional if needed.
Week by week
Is it right for you?
Setmelanotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Does the same job twice, with a higher risk of side effects linked to the melanocortin (a hormone system controlling pigment and appetite) system, including too much skin darkening (hyperpigmentation)
Possible unpredictable interactions with melanocortin (a hormone system controlling pigment and appetite) signaling (the brain's hunger-control chain), which may change how well the drug works or how safe it is
May worsen skin color changes and raise the risk of new moles (melanocytic nevi) when the MC1R receptor (which controls skin pigment) is switched on
Essential for confirming gene changes in the melanocortin (a hormone system controlling pigment and appetite) pathway (the brain's hunger-control chain) and finding patients who can take this targeted drug (an MC4R agonist, which switches on the MC4R hunger receptor)
A helpful addition that supports diet and lifestyle changes alongside the drug's effect on hunger
Supports healthy eating habits as extreme hunger (hyperphagia) fades and appetite returns to normal with treatment
Generally safe to take alongside Setmelanotide. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 16.
Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 16.
Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 6.
Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin (a hormone system controlling pigment and appetite) pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 2.
Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) 6 due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. 6 Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients 6.
Safety evidence comes from Phase 3 trials (IMCIVREE, VENTURE) in pediatric and adult populations with confirmed genetic melanocortin (a hormone system controlling pigment and appetite) pathway defects, 26 with long-term follow-up data supporting chronic administration. FDA approval in 2020 and EMA approval in 2021 validate the benefit-risk profile in eligible populations. Acquired hypothalamic (the brain region that runs your hormone system) obesity has since been added to the FDA-approved indications (label revised 4/2026) 6; studies in Prader-Willi syndrome and Alström syndrome continue to characterize safety in other forms of obesity.
Keeping it good
Store Setmelanotide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Setmelanotide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2021
Setmelanotide is the first FDA-approved medicine for a rare form of genetic obesity caused by defects in the brain's appetite control center. It switches on the melanocortin-4 receptor (a docking site on brain cells that controls hunger) to restore normal hunger signals in people with POMC, PCSK1, or leptin receptor deficiency.
Markham A
2025
In a study of very young children (ages 2-5) with genetic obesity, setmelanotide reduced BMI (body mass index) by an average of 18 percent and cut hunger by 91 percent in caregivers' reports. This made it the first treatment option for this age group with rare genetic forms of severe early-onset obesity.
Argente J, Verge CF, Okorie U, et al.
2024
Setmelanotide represents a breakthrough in treating monogenic obesity (obesity caused by a change in a single gene) by directly switching on the brain's appetite-control receptor. It offers hope for people with severe genetic obesity from POMC, PCSK1, and other leptin-melanocortin pathway defects (faults in the brain's hunger-control chain) that cause extreme hunger and early-onset weight gain.
Qamar S, Mallik R, Makaronidis J, et al.
2025
Clinical evidence supports setmelanotide's effectiveness in managing rare genetic forms of severe obesity and hyperphagia.
Sun Y, Abed M, Sohouli MH, et al.
2025
Setmelanotide demonstrates sustained efficacy in long-term weight management for patients with genetic obesity disorders.
Peng J, Ou Y, Zhou M, et al.
2024
Rhythm Pharmaceuticals (FDA / DailyMed)
If this isn't the right fit
Your questions
Setmelanotide is approved for patients aged 6 years and older with obesity caused by genetically confirmed POMC (proopiomelanocortin) deficiency, PCSK1 (proprotein convertase subtilisin/kexin type 1) deficiency, LEPR (leptin receptor) deficiency, or Bardet-Biedl syndrome. These are rare inherited conditions that disrupt appetite control. Genetic testing to confirm one of them is required before starting. It is not approved for common (polygenic) obesity.
Setmelanotide switches on MC4R to reduce appetite, but it also has some effect on MC1R (melanocortin-1 receptor), a docking site on skin pigment cells. MC1R makes the skin produce melanin, which darkens the skin. This is similar to how alpha-MSH (the body's natural version) causes tanning. Setmelanotide is about 20 times more selective for MC4R than MC1R, but the MC1R effect is still enough to cause noticeable skin darkening in most patients.
Setmelanotide addresses the symptom (hyperphagia and obesity) but does not correct the underlying genetic defect. If treatment is discontinued, hyperphagia and weight regain are expected to return as MC4R is no longer being directly stimulated. Long-term, continuous treatment is generally necessary to maintain the benefit.
Setmelanotide works in a completely different way. It targets the melanocortin-4 receptor (MC4R, a docking site in the brain's appetite center, the hypothalamus (the brain region that runs your hormone system)) that is part of the body's leptin-melanocortin appetite pathway. GLP-1 (a gut hormone that tells your brain you're full) drugs like semaglutide work through the incretin system (gut hormones), affecting insulin, glucagon (a hormone that raises blood sugar), and how fast the stomach empties. Setmelanotide is uniquely effective in patients with genetic defects in the melanocortin pathway, where GLP-1 drugs may work less well, because the basic problem is a broken "I'm full" signal through MC4R.
Yes, setmelanotide is approved for patients aged 6 years and older with qualifying genetic obesity conditions. The VENTURE trial specifically studied children aged 2-5 years, showing 83% achieved meaningful BMI reduction with a favorable safety profile. Pediatric dosing starts at 0.5 mg once daily with careful titration (stepping the dose up gradually).
Yes, genetic testing confirming POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome is required before treatment. Setmelanotide works by bypassing upstream genetic defects in the melanocortin (a hormone system controlling pigment and appetite) pathway, so it is only effective when these specific mutations are present. Rhythm Pharmaceuticals offers a free genetic testing program (Uncovering Rare Obesity) to help identify eligible patients.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Setmelanotide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek